Carlsmed delivered Q1 2026 revenue of $16.1 million, representing 58% growth year-over-year, with full year 2026 revenue guidance raised to $72-$77 million. The company achieved 86% revenue growth in 2025, driven by strong lumbar platform performance and new cervical product launches, with gross margins expanding to 75.3%. Carlsmed began trading on the Nasdaq Global Select Market under ticker CARL on July 23, 2025.
Cyborg Score Rationale
Carlsmed demonstrates exceptional commercial momentum with 58% YoY growth in Q1 2026, strong gross margins at 75.3%, and successful product expansion from lumbar to cervical spine procedures. Recent IPO (July 2025) with solid institutional backing, validated by analyst Buy ratings. Clinical data shows 74% reduction in reoperations, supporting differentiation.
Top Insights
(May 2026) Full-year 2026 revenue guidance raised to $72-77M, implying 44% expected growth at midpoint, reflecting strong Q1 execution
(Q1 2026) 58% YoY revenue growth with gross margin of 75.3%, demonstrating operational leverage and commercial traction
Dual-platform expansion into cervical spine procedures (launched 2025 first case, commercial launch 2026) diversifies revenue beyond lumbar lumbar market
Strong clinical validation with 74% reduction in reoperations and peer-reviewed publications in Global Spine Journal supporting competitive positioning
Named Competitors
Globus Medical — AI-enabled surgical planning and personalized spine solutions
NuVasive — Digital spine surgery platform with AI-enabled surgical planning
Arthrex — Personalized orthopedic surgical solutions and implants
ChoiceSpine — Patient-specific spine implants and surgical planning
Recent Developments
(May 2026) Full year 2026 revenue guidance raised to $72-77 million; Q1 2026 revenue $16.1 million
(February 2026) Full year 2025 revenue reported at $50.5 million with 86% YoY growth; Q4 2025 revenue $15.2 million
(July 2025) IPO priced at $15/share with Nasdaq listing under ticker CARL
(July 2025) First personalized cervical spine surgery completed using aprevo® platform
Open the full interactive Carlsmed, Inc. report
Strategic research, analyst-debate audio, full Cyborg Score breakdown across 11 dimensions, and saved-company audio playlists.